Table 1. Baseline characteristics of the PiREM study cohort.
Values are presented as median (Q1-Q3) and frequencies are presented as n (%).
T2D: type 2 diabetes; HbA1c: glycosylated hemoglobin; HOMA-IR: homeostatic model assessment of insulin resistance; LDL: low-density lipoprotein; HDL: high-density lipoprotein; MR FFM: magnetic resonance fat fraction mapping; GLP-1: glucagon-like peptide 1.
| Variable | Value |
| Gender: male/female | 5 (50%)/5 (50%) |
| Age (years) | 52 (43-56) |
| Duration of T2D (years) | 1.5 (1.1-5.3) |
| Weight (kg) | 100.9 (95.3-111.6) |
| BMI (kg/m2) | 33.1 (32.1-37.7) |
| Waist circumference (cm) | 107 (104-121) |
| Hip circumference (cm) | 111 (105.5-120) |
| Fasting plasma glucose (mmol/l) | 9.3 (7.6-9.8) |
| Fasting plasma glucose (mg/dl) | 167 (137-176) |
| Fasting insulin (pmol/l) | 152.1 (121.5-320.2) |
| HbA1c (mmol/mol) | 57.0 (52.0-63.0) |
| HbA1c(%) | 7.4 (6.9-7.9) |
| HOMA-IR | 8.7 (6.5-22.1) |
| Systolic blood pressure (mmHg) | 144 (128-146) |
| Diastolic blood pressure (mmHg) | 92 (85-98) |
| Triglycerides (mmol/l) | 2.4 (1.5-3.6) |
| Triglycerides (mg/dL) | 212 (135-315) |
| Cholesterol (mmol/l) | 4.7 (4.3-5.4) |
| Cholesterol (mg/dL) | 180 (167-209) |
| LDL cholesterol (mmol/l) (missing n = 1) | 2.5 (2.0-3.2) |
| LDL cholesterol (mg/dL) (missing n = 1) | 95 (76-125) |
| HDL cholesterol (mmol/l) | 1.3 (1.0-1.5) |
| HDL cholesterol (mg/dL) | 49 (39-57) |
| Body fat percentage (%) | 42.1 (31.9-47.5) |
| Liver fat (MR FFM) (%) (missing n = 2) | 20.6 (16.6-25.5) |
| Pancreas fat (MR FFM) (%) (missing n = 2) | 1.70 (1.22-2.61) |
| Acute insulin response (µIU/ml) | 58.4 (48.1- 100.9) |
| Total number of oral glucose-lowering medication | |
| 0 | 5 (50%) |
| 1 | 4 (40%) |
| ≥2 | 1 (10%) |
| GLP-1 analog | 1/10 (10%) |
| Basal insulin | 1/10 (10%) |